RenalSense, announced a distribution agreement with Medtechnica. Medtechnica will market RenalSense's Clarity RMS critical care monitoring system to hospitals throughout Israel. Clarity RMS has been clinically proven to facilitate early detection of changes in renal function and Acute Kidney Injury risk, and is installed in a number of intensive care units in leading medical centers around the world. The system continuously measures urine flow, automatically transmitting real-time data and notifications of fluctuations to enable rapid intervention, monitoring of treatment efficacy and fluid management. Clarity RMS is marketed in Europe, the Middle East, and Africa by Fresenius Medical Care. RenalSense is currently in discussions with additional partners regarding distribution agreements for other key markets.